Jiangsu COAST PHARMACEUTICAL CO., LTD

The pharmacokinetic behavior of the test formulation of posaconazole enteric-coated tablets (specification: 100 mg, Yangtze River Pharmaceutical Group Co., Ltd.) and the reference formulation (NocoFy®, specification: 100 mg, licensee: Merck Sharp & Dohme Ltd; manufacturer: N.V.Organon) in healthy subjects after a single oral administration in the fasting and postprandial state was studied to evaluate the bioequivalence of the two formulations. The safety of the test formulation and the reference formulation (trade name: NocoFy®) in healthy subjects was evaluated.

The pharmacokinetic behavior of the single-use crisaborole ointment test formulation (Specification: 20 mg crisaborole (2%) per gram of this product, provided by Jiangsu Coast Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Sutanming®/Staquis®, Specification: 20 mg crisaborole (2%) per gram of this product, Pharmacia and Upjohn Company LLC) in healthy subjects was studied to evaluate the bioequivalence of the two formulations. The safety of the test formulation and the reference formulation (trade name: Sutanming®/Staquis®) in healthy subjects was observed.

The primary objective was to study the pharmacokinetic behavior of aprepitant capsules (specification: 125 mg, manufacturer: Jiangsu Coast Pharmaceutical Co., Ltd.) and reference preparation (trade name: Yimei, specification: 125 mg, licensee: Merck Sharp & Dohme Ltd.) in healthy subjects after a single oral administration under fasting and postprandial conditions, and to evaluate the bioequivalence of the two preparations. The secondary objective was to observe the safety of the test preparation and reference preparation (trade name: Yimei) in healthy subjects.